12:43 PM
Nov 06, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Adenocarcinoma

Mouse studies suggest dual inhibition of MCL1 and MEK could help treat KRAS-mutant adenocarcinoma. In seven patient-derived xenograft (PDX) mouse models of KRAS-mutant adenocarcinoma, the MCL1 inhibitor AMG 176 plus the MEK inhibitor Mekinist trametinib increased tumor regression compared...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >